A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

PHASE2RecruitingINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

March 28, 2027

Study Completion Date

August 15, 2027

Conditions
Asthma
Interventions
DRUG

PF-07275315

subcutaneous injection

OTHER

Placebo

subcutaneous injection

Trial Locations (16)

29732

NOT_YET_RECRUITING

Clinical Research of Rock Hill, Rock Hill

36608

NOT_YET_RECRUITING

Velocity Clinical Research, Mobile, Mobile

37075

NOT_YET_RECRUITING

Premier Research Center, LLC, Hendersonville

73034

NOT_YET_RECRUITING

OK Clinical Research, Edmond

73120

RECRUITING

Allergy, Asthma and Clinical Research, Oklahoma City

75209

NOT_YET_RECRUITING

Alina Clinical Trials, LLC., Dallas

77008

RECRUITING

Greater Heights & Memorial Pulmonary and Sleep, Houston

93534

RECRUITING

Antelope Valley Clinical Trials, Lancaster

94598

RECRUITING

Allergy & Asthma Clinical Research, Walnut Creek

95117

RECRUITING

Allergy and Asthma Associates of Santa Clara Valley Research Center, San Jose

200080

NOT_YET_RECRUITING

Shanghai General Hospital, Shanghai

510150

NOT_YET_RECRUITING

The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou

07457

NOT_YET_RECRUITING

Circuit Clinical / Impact Medical Allergy, Asthma & Immunology, Riverdale

586-8521

NOT_YET_RECRUITING

National Hospital Organization Osaka Minami Medical Center, Kawachi-Nagano

591-8555

NOT_YET_RECRUITING

NHO Kinki Chuo Chest Medical Center, Sakai

104-0031

NOT_YET_RECRUITING

Fukuwa Clinic, Chuo-ku

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06977581 - A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | Biotech Hunter | Biotech Hunter